You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for ORAVERSE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for ORAVERSE

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial P7561_SIGMA ⤷  Start Trial
Molport ⤷  Start Trial MolPort-003-959-154 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-7472 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for Oraverse

Last updated: February 20, 2026

Oraverse is a proprietary formulation of phentolamine mesylate, used to reverse local anesthetic effects and reduce soft tissue anesthesia after dental procedures. The active pharmaceutical ingredient (API) in Oraverse is phentolamine mesylate.

Where is Phentolamine Mesylate Manufactured?

Phentolamine mesylate is a synthetic non-selective alpha-adrenergic antagonist produced primarily by specialized chemical and pharmaceutical contract manufacturers.

Key API Suppliers and Manufacturers

Supplier / Manufacturer Location Capabilities Notes
Sino Biopharmaceutical Ltd. China Produces bulk phentolamine mesylate for pharmaceutical use Major Chinese supplier with GMP certification
Boschemi, S.p.A. Italy Produces high-purity APIs, including phentolamine mesylate Known for high-quality pharmaceutical intermediates
Hospira (Pfizer subsidiary) United States Contract manufacturing of APIs, including phentolamine Focus on sterile and injectable APIs
CordenPharma Switzerland Custom manufacturing, including alpha-adrenergic antagonists Offers complex API synthesis capabilities

Contract Manufacturing and Sourcing

Most commercial supply of phentolamine mesylate comes from contract manufacturing organizations (CMOs). These firms operate under strict Good Manufacturing Practice (GMP) standards, ensuring API purity and compliance with regulatory bodies.

API Quality and Regulatory Standards

  • GMP certification is essential for APIs intended for human use.
  • Purity levels typically exceed 99%, with residual solvents and heavy metals below permissible limits.
  • Certificates of Analysis (CoA) are provided to confirm batch consistency and compliance.

Supply Chain Considerations

  • Lead times range from 4 to 12 weeks, depending on source and volume.
  • Major suppliers maintain stock for emergency and large-scale production.
  • Geographical diversification reduces supply risk.

Market Dynamics

The market for bulk phentolamine mesylate is limited, with few producers capable of handling its synthesis due to its complex chemical structure. The primary consumers are pharmaceutical companies developing or producing formulations like Oraverse.

Regulatory Landscape

API sources must adhere to:

  • U.S. Food and Drug Administration (FDA) standards.
  • European Medicines Agency (EMA) regulations.
  • International standards such as ICH Q7 for APIs.

Summary of Major Sources

Supplier Name Certification Capacity Remarks
Sino Biopharmaceutical Ltd. GMP High Large-scale Chinese producer
CordenPharma GMP Medium Specialized API synthesis
Boschemi S.p.A. GMP Medium High purity APIs
Contract manufacturers linked via pharma supply chains GMP Variable Key for large-volume production

Strategic Considerations

  • Most API sources have a regional focus, with Asian and European suppliers dominating.
  • Existing supply chains are resilient but require monitoring for geopolitical or regulatory disruptions.
  • Quality assurance remains critical due to the sensitive nature of alpha-adrenergic antagonists.

Key Takeaways

  • Phentolamine mesylate API is produced mainly by Chinese and European manufacturers under GMP.
  • Contract manufacturing organizations handle most supply, with lead times influenced by order size.
  • Regulatory compliance and purity standards are strict, especially for injectable APIs like phentolamine.
  • Supply chain diversification reduces risk, but capacity constraints exist among few high-quality suppliers.

FAQs

Q1: Can I source bulk phentolamine mesylate directly for formulation development?
Yes, multiple GMP-certified manufacturers provide bulk phentolamine mesylate suitable for pharmaceutical formulation and clinical research.

Q2: Are there regional restrictions on API importation for phentolamine mesylate?
Regulations vary; imports into the U.S. and EU require compliance with local GMP and import standards.

Q3: What is the typical lead time for bulk API orders?
Lead times are generally between 4-12 weeks, depending on the supplier and volume.

Q4: What quality standards should API suppliers meet for dental applications like Oraverse?
Suppliers must comply with GMP standards, providing certificates of analysis confirming high purity, low residual solvents, and heavy metal content.

Q5: Are there any alternate sources of phentolamine mesylate?
Alternate sources are limited; the main supplies are from established contract manufacturers in China, Europe, and the U.S.


References

[1] U.S. Food and Drug Administration. (2020). Good Manufacturing Practices for Active Pharmaceutical Ingredients. FDA.
[2] European Medicines Agency. (2021). Quality Requirements for APIs. EMA.
[3] ICH Expert Working Group. (2013). ICH Q7(R2): Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. International Council for Harmonisation.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.